Form 4: VolitionRx Director Phillip Barnes Reports Changes in Beneficial Ownership
SEC Form 4 Filing
Director Phillip Barnes reports the vesting of 5,000 restricted stock units (RSUs) and cancellation of 6,500 RSUs in VolitionRx Ltd.
Summary
- On August 15, 2024, Phillip Barnes, a director of VolitionRx Ltd, reported changes in his beneficial ownership of the company's stock.
- 5,000 restricted stock units (RSUs) vested due to the achievement of certain corporate performance goals.
- These RSUs are subject to a 3-year time-based vesting schedule, with installments vesting on September 28, 2024, 2025, and 2026.
- 6,500 RSUs did not vest and were cancelled on August 15, 2024.
- As of the report, Barnes directly owns 46,197 shares of common stock.
Sentiment
Score: 6
Explanation: The sentiment is neutral. While some RSUs vested, indicating achievement of performance goals, others were cancelled, suggesting some goals were not met. The overall impact is balanced.
Positives
- The vesting of RSUs indicates that certain corporate performance goals were achieved.
Negatives
- The cancellation of 6,500 RSUs suggests that some performance goals were not met.
Risks
- Future vesting of the remaining RSUs is contingent on continued time-based vesting.
Future Outlook
Future vesting of the remaining RSUs is contingent on continued time-based vesting.
Industry Context
This filing is a routine disclosure related to executive compensation and equity ownership, common in publicly traded companies. It provides transparency to investors regarding the holdings of company insiders.
Comparison to Industry Standards
- Equity compensation is a standard practice in the biotechnology industry to align the interests of executives with those of shareholders.
- The vesting schedules and performance-based conditions are typical components of RSU grants in comparable companies.
- Companies like Exact Sciences and Guardant Health also utilize RSUs as part of their executive compensation packages.
Stakeholder Impact
- The vesting of RSUs can be seen as a positive signal to shareholders, indicating that management is achieving certain performance goals.
- The cancellation of RSUs may raise concerns about the company's ability to meet all of its objectives.
Next Steps
- The remaining vested RSUs will continue to vest in installments on September 28, 2024, 2025, and 2026.
Key Dates
| Date | Description |
|---|---|
| Sept 28, 2023 | Reporting person was awarded 20,000 restricted stock units (RSUs). |
| Dec 31, 2023 | Initial performance goal deadline for RSU vesting. |
| Jan 2024 | Reported that 8,500 RSUs previously vested and remain subject to time-based vesting. |
| June 30, 2024 | Second performance goal deadline for RSU vesting. |
| 08/15/2024 | Date of transaction: 5,000 RSUs vested and 6,500 RSUs cancelled. |
| 08/16/2024 | Date of signature on the form. |
| Sept 28, 2024 | First installment of time-based vesting for vested RSUs. |
| Sept 28, 2025 | Second installment of time-based vesting for vested RSUs. |
| Sept 28, 2026 | Third installment of time-based vesting for vested RSUs. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.